Sun Pharmaceutical launches Fexuprazan tablets 40 mg in India
Under brand name "FEXUCLUE?"
Sun Pharmaceutical Industries has launched Fexuprazan tablets 40 mg in India under the brand name FEXUCLUE. FEXUCLUE, a novel potassium competitive acid blocker (PCAB), is approved as a new treatment for adults with Erosive Esophagitis of all grades.
Sun Pharma has obtained rights from Daewoong Pharmaceutical Co Ltd, Korea, a biopharmaceutical company, to manufacture and commercialise FEXUCLUE(Fexuprazan) in India. As per agreement terms, Daewoong will be entitled to upfront and milestone payments, including royalties.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content